Synthetic Biologics rallies after being awarded contract from CDC
Earlier today, Synthetic Biologics announced it has been awarded a contract by the Centers for Disease Control and Prevention, CDC. The award will support research conducted during the Company's ongoing randomized, placebo-controlled Phase 2b proof-of-concept clinical study of SYN-004, ribaxamase, designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous beta-lactam antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea and the emergence of antibiotic-resistant organisms. The contract, awarded through the CDC's Advanced and Innovative Solutions to Improve Public Health Broad Agency Announcement 2016-N-17812, will support CDC's efforts to assess how selective pressure from IV antibiotics may lead to the emergence of antibiotic resistance in the gut microbiome. The funding will also support research to evaluate ribaxamase's ability to reduce selective pressure associated with the emergence of antibiotic-resistant organisms in the gut microbiomes of patients enrolled in the Company's ongoing Phase 2b clinical trial. The Company will examine DNA isolated from longitudinal samples obtained during the clinical trial and look for changes to the patient's gut resistome, specifically examining for alterations in the presence and/or abundance of antibiotic resistance genes. Shares of Synthetic Biologics are up 2.76% or 5c to $1.82 in morning trading.